Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ROAD TOWN, BRITISH VIRGIN ISLANDS, OCT. 02, 2025 (GLOBE NEWSWIRE) -- AURA MINERALS INC.(NASDAQ: AUGO; B3: AURA33) (AURA OU COMPANHIA) ANNOUNCES TO THE HOLDERS OF THE COMPANY'S BRAZILIAN DEPOSITARY RECEIPTS ("BDRS") THE LAUNCH OF THE INCENTIVE PROGRAM FOR THE CONVERSION OF BDRS INTO COMMON SHARES (INCENTIVE PROGRAM), UNDER WHICH HOLDERS MAY REQUEST THE CONVERSION OF THEIR BDRS (AURA33) INTO THE UNDERLYING COMMON SHARES (AUGO) LISTED ON NASDAQ (COMMON SHARES), AT A RATIO OF THREE TO ONE, WITHOUT BEING REQUIRED TO PAY THE APPLICABLE FEES CHARGED BY BANCO BRADESCO. THE INCENTIVE PROGRAM WILL BE AVAILABLE FOR A FIXED PERIOD OF 32 DAYS, FROM OCTOBER 6, 2025, TO NOVEMBER 6, 2025 (SUBSIDY PERIOD).

INCENTIVE PROGRAM FOR THE CONVERSION OF BDRS INTO SHARES

THERE IS NO IMPACT TO THE CAPITAL COSTS OR ECONOMIC RESULTS. THE ONLY CHANGE IS A SLIGHTLY REVISED ALL-IN SUSTAINING COST FOR THE "BASE CASE" FROM $1,152 TO $1,172 PER GOLD OUNCE.

WESTERN EXPLORATION FILES AMENDED NI 43-101 TECHNICAL REPORT FOR THE AURA GOLD SILVER PROJECT

BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC.(NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAYANNOUNCED THATELISABET DELOS PINOS, PHD, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THEH.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE ONWEDNESDAY, SEPTEMBER 10, 2025, AT 11:00 A.M. ET.

AURA BIOSCIENCES TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

CONTINUED CLINICAL PROGRAM EXECUTION IN THE PHASE 3 COMPASS TRIAL IN EARLY CHOROIDAL MELANOMA AND THE PHASE 1B/2 TRIAL IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

AURA BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BOSTON, MAY 15, 2025 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (AURA) (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 11,735,565 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE AN AGGREGATE OF 2,933,891 SHARES OF COMMON STOCK AND (II) TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 3,571,435 SHARES OF ITS COMMON STOCK AT AN EXERCISE PRICE OF $0.00001 PER PRE-FUNDED WARRANT, AND ACCOMPANYING WARRANTS TO PURCHASE UP TO 892,858 SHARES OF ITS COMMON STOCK. THE COMMON STOCK AND PRE-FUNDED WARRANTS ARE BEING SOLD IN COMBINATION WITH AN ACCOMPANYING WARRANT TO PURCHASE 0.25 OF A SHARE OF COMMON STOCK ISSUED FOR EACH SHARE OF COMMON STOCK OR PRE-FUNDED WARRANT SOLD. THE ACCOMPANYING COMMON STOCK WARRANT HAS AN EXERCISE PRICE OF $4.90 PER SHARE, IS IMMEDIATELY EXERCISABLE FROM THE DATE OF ISSUANCE AND WILL EXPIRE FIVE YEARS FROM THE DATE OF ISSUANCE. THE COMBINED OFFERING PRICE OF EACH SHARE OF COMMON STOCK AND ACCOMPANYING COMMON STOCK WARRANT IS $4.90. THE COMBINED OFFERING PRICE OF EACH PRE-FUNDED WARRANT AND ACCOMPANYING COMMON STOCK WARRANT IS $4.89999.

AURA BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BOSTON, MAY 15, 2025 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (AURA) (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK AND, TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS AND ACCOMPANYING COMMON STOCK WARRANTS TO BE SOLD IN THE OFFERING WILL BE OFFERED BY AURA. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

AURA BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

FIRST PATIENT ENROLLED IN MULTI-DOSE PHASE 1B/2 TRIAL OF BEL-SAR IN NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC); INITIAL DATA AT 3 MONTHS EXPECTED BY YEAR-END 2025

AURA BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BOSTON, MAY 01, 2025 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC.(NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THATMEMBERS OF ITSSENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

AURA BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

BOSTON, APRIL 02, 2025 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE APPOINTMENT OF TERESA BITETTI, PRESIDENT OF THE GLOBAL ONCOLOGY BUSINESS UNIT AT TAKEDA, TO THE COMPANY'S BOARD OF DIRECTORS, EFFECTIVE MARCH 31, 2025.

AURA BIOSCIENCES ANNOUNCES APPOINTMENT OF TERESA BITETTI TO BOARD OF DIRECTORS

POSITIVE PHASE 1 TRIAL DATA IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PRESENTED AT THE 40TH ANNUAL EUROPEAN ASSOCIATION OF UROLOGY CONGRESS; SUPPORTS FRONT-LINE TREATMENT POTENTIAL

Aura Biosciences, Inc.

AURA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aura Biosciences, Inc.

AURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AURA